Skip to main content
. 2022 Jun 18;15:1877–1884. doi: 10.2147/DMSO.S361808

Table 1.

Comparison of the Clinical Characteristics of Patients with T2DM in the Community Between Those with DN and Those without DN

Characteristics Total Male Female
Normal (n= 172) Microalbuminuria (n=221) Massive Albuminuria (n= 105) P for Trend Normal (n=112) Microalbuminuria (n= 126) Massive Albuminuria (n= 60) P for Trend Normal (n=60) Microalbuminuria (n=95) Massive Albuminuria (n=45) P for Trend
Age (y) 55±13 60±14 60±13 0.005 53±13 57±14 57±13 0.020 59±11 63±14 63±11 0.255
*Duration (y) 10 (3, 15) 11 (6, 17) 15 (9.5, 19) <0.01 8 (2, 13) 11 (6, 16) 14 (7, 18.8) <0.01 12 (4.3, 18.8) 11 (5, 20) 16 (13, 20) 0.040
BMI, kg/cm2 25.6±3.7 26.3±4.3 26.9±4.0 0.009 25.8±3.7 26.9±4.2 26.9±4.0 0.055 25.3±3.8 25.5±4.3 27.0±4.1 0.044
SBP (mmHg) 130±17 136±17 144±22 <0.01 129±16 135±17 143±20 <0.01 132±19 138±18 146±25 0.001
DBP (mmHg) 79±11 80±12 81±11 0.106 80±10 81±12 84±11 0.066 77±11 78±11 79±10 0.484
*AST (IU/L) 18 (14, 23) 19 (14, 26) 17 (13, 22) 0.190 18 (15, 24) 18 (14, 25.3) 17 (13, 24) 0.328 18 (13, 21) 19 (14, 26) 17 (13, 21) 0.411
*ALT (IU/L) 18 (14, 23) 19 (12, 31) 14 (11, 22.5) 0.034 20 (14, 33.5) 21 (13, 32.3) 17 (12.3, 26) 0.128 16 (12, 22) 16 (11, 27) 13 (9.5, 18.5) 0.219
*TG (mmol/L) 1.5 (1.0, 2.3) 1.7 (1.2, 2.5) 1.8 (1.1, 2.4) <0.01 1.5 (1.0, 2.3) 1.8 (1.2, 2.5) 1.7 (11.0, 2.3) <0.01 1.4 (1.0, 2.2) 1.6 (1.3, 2.4) 2.1 (1.4, 2.7) 0.005
TC (mmol/L) 4.6±1.1 4.5±1.3 4.9±1.2 0.066 4.6±1.0 4.4±1.4 4.8±1.0 0.452 4.6±1.1 4.7±1.1 5.1±1.4 0.072
HDL-C (mmol/L) 0.98±0.24 0.93±0.21 1.01±0.29 0.611 0.95±0.25 0.87±0.19 0.98±0.29 0.879 1.05±0.22 1.01±0.21 1.06±0.28 0.929
LDL-C (mmol/L) 2.72±0.8 2.59±0.90 2.85±0.81 0.386 2.74±0.73 2.46±0.82 2.82±0.72 0.921 2.68±0.94 2.75±0.97 2.91±0.92 0.233
FPG (mmol/L) 8.3±3.0 8.7±3.1 9.5±3.1 0.002 8.5±3.3 8.8±3.0 9.5±3.2 0.049 8.0±2.7 8.6±3.2 9.5±2.9 0.009
PPG (mmol/L) 12.5±4.4 13.3±4.1 12.3±4.1 0.939 12.6±4.7 13.5±4.2 12.1±4.1 0.828 12.2±3.9 13.1±4.0 12.5±4.1 0.625
HbA1c (%) 8.8±2.2 9.2±2.0 9.4±2.2 0.040 9.0±2.3 9.3±2.0 9.3±2.2 0.262 8.7±1.8 9.2±2.0 9.4±2.1 0.043
SUA (µmol/L) 315.4±85.0 339.9±91.4 368.8±96.5 <0.01 334.4±87.3 355.2±89.4 384.5±98.1 0.001 279.9±68.1 319.6±90.6 347.8±91.0 <0.01
* CRE (µmol/L) 62 (53.3, 74.5) 66 (54, 79) 81 (62.5, 120) <0.01 67 (58, 78.8) 71 (61, 83.3) (67.5, 128) <0.01 52.5 (46, 60) 58 (47, 68) 67 (57.5, 98) <0.01
eGFR (mL/min/1.73 m2) 149.4±27.5 145.0±28.7 121.1±40 <0.01 140.7±21.8 136.1±23.2 111.1±33.5 <0.01 165.6±29.9 156.9±31.1 134.3±44.3 <0.01
Asprosin (pg/mL) 314.2±81.1 338.6±89.7 365.0±88.5 <0.01 332.6±81.7 352.8±86.7 377.9±85.0 <0.01 279.9±68.1 319.7±90.6 347.9±91.0 <0.01
ACEI/ARB n (%) 8 (4.7) 27 (12.2) 10 (9.5) 0.086 5 (4.5%) 16 (12.7) 7 (11.7) 0.065 3 (5) 11 (11.6) 3 (11.6) 0.656

Note: *Kruskal–Wallis H-test.

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FPG, fasting blood glucose; PPG, blood glucose at 2 hours after meals; HbA1c, glycosylated haemoglobin; SUA, serum uric acid; CRE, creatinine; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; ACEI/ARB n, ACEI/ARB therapy.